Comparison of Survival Rates Based on Recommended Treatment Algorithms of BCLC or HKLC Staging Systems for Hepatocellar Carcinoma Patients
Objective To evaluate the effect of the recommended treatment algorithms of the Barcelona Clinic Liver Cancer (BCLC) or Hong Kong Liver Cancer (HKLC) staging systems on the survival rate of patients with HCC. Methods A total of 436 patients newly diagnosed as HCC were analyzed. The prognostic perfor...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Magazine House of Cancer Research on Prevention and Treatment
2019-04-01
|
| Series: | Zhongliu Fangzhi Yanjiu |
| Subjects: | |
| Online Access: | http://html.rhhz.net/ZLFZYJ/html/8578.2019.18.1340.htm |
| _version_ | 1818190297406898176 |
|---|---|
| author | DENG Guoyu CHEN Jie HUANG Shan LI Kezhi HE Jianbo WU Guobin CHEN Chuang |
| author_facet | DENG Guoyu CHEN Jie HUANG Shan LI Kezhi HE Jianbo WU Guobin CHEN Chuang |
| author_sort | DENG Guoyu |
| collection | DOAJ |
| description | Objective To evaluate the effect of the recommended treatment algorithms of the Barcelona Clinic Liver Cancer (BCLC) or Hong Kong Liver Cancer (HKLC) staging systems on the survival rate of patients with HCC. Methods A total of 436 patients newly diagnosed as HCC were analyzed. The prognostic performance and efficacy of treatment recommendations were compared between the two systems. All patients were first classified into a tumour stage according to the HKLC and BCLC staging systems respectively, and then they were divided into groups depending on whether they ultimately received the treatment recommended by the two staging systems. The efficacy of treatment algorithms of BCLC and HKLC systems was evaluated by comparing the patients who received treatment recommendations of either BCLC or HKLC stage to those who did not. Results HCC patients who received the recommended treatment algorithms of the BCLC and HKLC systems had a significantly favourable 5-year survival probability compared with the patients who did not (BCLC: 48% vs. 30%, P < 0.001; HKLC: 41% vs. 29%, P < 0.001). Patients receiving resection had a significantly favourable 5-year survival rate in BCLC-B/HKLC-Ⅰ+Ⅱa+Ⅱb, BCLC-B/HKLC-Ⅲa+Ⅲb and BCLC-C/HKLC-Ⅲa+Ⅲb groups than those receiving TACE, Sorafenib or best supportive care(all P < 0.05). Conclusion The recommended treatment algorithms of the BCLC and HKLC systems could improve survival rates of HCC patients. Curative therapies are superior to standard of care for BCLC-B/HKLC-Ⅰ+Ⅱa+Ⅱb, BCLC-B/HKLC-Ⅲa+Ⅲb and BCLC-C/HKLC-Ⅲa+Ⅲb patients. Some patients can achieve better survival through active radical treatment. |
| first_indexed | 2024-12-11T23:56:28Z |
| format | Article |
| id | doaj.art-f21b3720f0a34602a3cc2e6498e7e456 |
| institution | Directory Open Access Journal |
| issn | 1000-8578 1000-8578 |
| language | zho |
| last_indexed | 2024-12-11T23:56:28Z |
| publishDate | 2019-04-01 |
| publisher | Magazine House of Cancer Research on Prevention and Treatment |
| record_format | Article |
| series | Zhongliu Fangzhi Yanjiu |
| spelling | doaj.art-f21b3720f0a34602a3cc2e6498e7e4562022-12-22T00:45:21ZzhoMagazine House of Cancer Research on Prevention and TreatmentZhongliu Fangzhi Yanjiu1000-85781000-85782019-04-0146432733210.3971/j.issn.1000-8578.2019.18.13408578.2019.18.1340Comparison of Survival Rates Based on Recommended Treatment Algorithms of BCLC or HKLC Staging Systems for Hepatocellar Carcinoma PatientsDENG Guoyu0CHEN Jie1HUANG Shan2LI Kezhi3HE Jianbo4WU Guobin5CHEN Chuang6Traditional Chinese Medicine Department of Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, ChinaOncology Department of Yulin First People's Hospital, Yulin 537000, ChinaTraditional Chinese Medicine Department of Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, ChinaTraditional Chinese Medicine Department of Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, ChinaTraditional Chinese Medicine Department of Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, ChinaTraditional Chinese Medicine Department of Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, ChinaTraditional Chinese Medicine Department of Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, ChinaObjective To evaluate the effect of the recommended treatment algorithms of the Barcelona Clinic Liver Cancer (BCLC) or Hong Kong Liver Cancer (HKLC) staging systems on the survival rate of patients with HCC. Methods A total of 436 patients newly diagnosed as HCC were analyzed. The prognostic performance and efficacy of treatment recommendations were compared between the two systems. All patients were first classified into a tumour stage according to the HKLC and BCLC staging systems respectively, and then they were divided into groups depending on whether they ultimately received the treatment recommended by the two staging systems. The efficacy of treatment algorithms of BCLC and HKLC systems was evaluated by comparing the patients who received treatment recommendations of either BCLC or HKLC stage to those who did not. Results HCC patients who received the recommended treatment algorithms of the BCLC and HKLC systems had a significantly favourable 5-year survival probability compared with the patients who did not (BCLC: 48% vs. 30%, P < 0.001; HKLC: 41% vs. 29%, P < 0.001). Patients receiving resection had a significantly favourable 5-year survival rate in BCLC-B/HKLC-Ⅰ+Ⅱa+Ⅱb, BCLC-B/HKLC-Ⅲa+Ⅲb and BCLC-C/HKLC-Ⅲa+Ⅲb groups than those receiving TACE, Sorafenib or best supportive care(all P < 0.05). Conclusion The recommended treatment algorithms of the BCLC and HKLC systems could improve survival rates of HCC patients. Curative therapies are superior to standard of care for BCLC-B/HKLC-Ⅰ+Ⅱa+Ⅱb, BCLC-B/HKLC-Ⅲa+Ⅲb and BCLC-C/HKLC-Ⅲa+Ⅲb patients. Some patients can achieve better survival through active radical treatment.http://html.rhhz.net/ZLFZYJ/html/8578.2019.18.1340.htmprimary liver cancerhepatocellular carcinomabarcelona clinic liver cancer staginghong kong liver cancer stagingprognosis |
| spellingShingle | DENG Guoyu CHEN Jie HUANG Shan LI Kezhi HE Jianbo WU Guobin CHEN Chuang Comparison of Survival Rates Based on Recommended Treatment Algorithms of BCLC or HKLC Staging Systems for Hepatocellar Carcinoma Patients Zhongliu Fangzhi Yanjiu primary liver cancer hepatocellular carcinoma barcelona clinic liver cancer staging hong kong liver cancer staging prognosis |
| title | Comparison of Survival Rates Based on Recommended Treatment Algorithms of BCLC or HKLC Staging Systems for Hepatocellar Carcinoma Patients |
| title_full | Comparison of Survival Rates Based on Recommended Treatment Algorithms of BCLC or HKLC Staging Systems for Hepatocellar Carcinoma Patients |
| title_fullStr | Comparison of Survival Rates Based on Recommended Treatment Algorithms of BCLC or HKLC Staging Systems for Hepatocellar Carcinoma Patients |
| title_full_unstemmed | Comparison of Survival Rates Based on Recommended Treatment Algorithms of BCLC or HKLC Staging Systems for Hepatocellar Carcinoma Patients |
| title_short | Comparison of Survival Rates Based on Recommended Treatment Algorithms of BCLC or HKLC Staging Systems for Hepatocellar Carcinoma Patients |
| title_sort | comparison of survival rates based on recommended treatment algorithms of bclc or hklc staging systems for hepatocellar carcinoma patients |
| topic | primary liver cancer hepatocellular carcinoma barcelona clinic liver cancer staging hong kong liver cancer staging prognosis |
| url | http://html.rhhz.net/ZLFZYJ/html/8578.2019.18.1340.htm |
| work_keys_str_mv | AT dengguoyu comparisonofsurvivalratesbasedonrecommendedtreatmentalgorithmsofbclcorhklcstagingsystemsforhepatocellarcarcinomapatients AT chenjie comparisonofsurvivalratesbasedonrecommendedtreatmentalgorithmsofbclcorhklcstagingsystemsforhepatocellarcarcinomapatients AT huangshan comparisonofsurvivalratesbasedonrecommendedtreatmentalgorithmsofbclcorhklcstagingsystemsforhepatocellarcarcinomapatients AT likezhi comparisonofsurvivalratesbasedonrecommendedtreatmentalgorithmsofbclcorhklcstagingsystemsforhepatocellarcarcinomapatients AT hejianbo comparisonofsurvivalratesbasedonrecommendedtreatmentalgorithmsofbclcorhklcstagingsystemsforhepatocellarcarcinomapatients AT wuguobin comparisonofsurvivalratesbasedonrecommendedtreatmentalgorithmsofbclcorhklcstagingsystemsforhepatocellarcarcinomapatients AT chenchuang comparisonofsurvivalratesbasedonrecommendedtreatmentalgorithmsofbclcorhklcstagingsystemsforhepatocellarcarcinomapatients |